The short version of Reversed-phase HPLC fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-01-05. Anything still debated is marked as such rather than presented as settled.
临床研究将Tα1用于慢性病毒感染、肿瘤辅助治疗和疫苗佐剂等场景。部分试验报告了免疫学指标改善，但临床终点获益在不同研究中并不一致。系统综述指出，研究间在人群、剂量和联合方案上差异较大，难以汇总结论。因此，Tα1的确切临床地位仍属开放问题，需要更多高质量随机对照试验来澄清。其机制研究也需从体外实验向体内模型推进。
胸腺素α1对免疫系统的影响涉及多种细胞类型。研究表明，它可促进未成熟T细胞向成熟T细胞分化，并增强T细胞对抗原刺激的增殖反应。树突状细胞在Tα1存在下表达更高水平的共刺激分子，从而更有效地呈递抗原。此外，自然杀伤细胞的活性也观察到上升。这些效应并非直接杀伤病原体，而是调节宿主免疫应答的强度与方向。
The activity of this peptide is generally described as immunomodulatory rather than directly antimicrobial. Experimental work links it to signaling through certain Toll-like receptors on dendritic cells and to downstream maturation of antigen-presenting cells. Reported effects include expansion of T cell subsets, shifts in cytokine profiles, and increased natural killer cell activity. These observations come largely from cell culture and animal models, and the precise receptor-level events in humans remain incompletely characterized.
The compound has been investigated as an adjunct in chronic viral hepatitis and as a vaccine adjuvant, with results that vary by study design and population. Regulators in some countries have approved a synthetic form for specific indications, while other agencies have not. Whether the peptide produces consistent clinical benefit across diverse patient groups is still an open question, and many trials have been small. Its status is therefore best described as investigational in many contexts and established only narrowly.
The name itself causes confusion, because several unrelated thymic peptides share the thymosin label. Thymosin beta-4, for example, is a different molecule with different functions. Naming conventions in the literature also mix descriptive research terms with assigned nonproprietary names, so a reader should confirm which entity a given paper addresses. Clarifying that point is usually the first step in interpreting any claim about this peptide.
| Property | Value | Notes |
|---|---|---|
| 主要靶细胞 | T细胞、树突状细胞 | 也影响NK细胞 |
| 信号通路 | TLR/MyD88/NF-κB | 部分实验模型 |
| 细胞因子偏向 | Th1型 | 增加IL-2、IFN-γ |
| 给药途径 | 皮下注射 | 临床常用 |
| 半衰期 | 约2小时 | 血浆中较短 |
The peptide lacks cysteine, methionine, and tryptophan, so disulfide scrambling and sulfur oxidation are not major degradation routes. Instead, aspartate residues can undergo isomerization or cyclization to succinimide intermediates, generating isoaspartate variants. Hydrolysis of peptide bonds also occurs slowly in solution. These changes may reduce biological activity even when the main peak remains detectable. Stability studies therefore track both potency and the appearance of related substances.
Lyophilized thymosin alpha 1 is typically stored refrigerated at 2 to 8 degrees Celsius and kept away from light. Reconstituted solutions are less stable and are usually used promptly after preparation. Repeated freeze-thaw cycles are avoided because they can promote aggregation and loss of activity. The peptide adsorbs to some plastic and glass surfaces, so a carrier protein is often added to dilute working solutions. Manufacturer instructions and published protocols both govern handling.
Identity and purity testing for thymosin alpha 1 relies mainly on reversed-phase high-performance liquid chromatography and mass spectrometry. Chromatography separates the parent peptide from truncated or modified variants, while mass spectrometry confirms the expected molecular mass. Amino acid analysis and peptide mapping provide additional sequence confirmation. Counterion content, water content, and residual solvents are measured separately as part of specification testing. No single method captures every attribute, so laboratories combine several techniques.
Long-term storage is generally at minus twenty degrees Celsius or colder, preferably desiccated and protected from light. Lyophilized material is more stable than reconstituted solution, which degrades faster at room temperature. Stability depends on pH, ionic strength, and the presence of oxidising agents. Published stability data for the peptide are limited, so storage claims in catalogues should be treated as general guidance rather than measured guarantees. Freeze-thaw cycles are kept to a minimum.
Identity and purity are normally confirmed by reversed-phase high-performance liquid chromatography and mass spectrometry. The expected mass for the acetylated 28-residue peptide is close to 3108 daltons, and a mass shift indicates a modification or truncation. Peptide mapping after enzymatic digestion can resolve sequence-level questions. Counter-ion content, water content, and residual solvents are separate quality attributes that a certificate of analysis may or may not report. Aggregation is monitored by size-exclusion chromatography when relevant.
Thymosin alpha-1 is supplied as a lyophilized powder in most research settings. The solid dissolves readily in water and in common aqueous buffers, and it is typically reconstituted shortly before use. Solutions are clear and colourless at ordinary working concentrations. Because the peptide is hygroscopic, weighing and reconstitution are usually performed with minimal exposure to ambient air. Aliquots are prepared to avoid repeated freeze-thaw cycles, and working solutions are kept cold.
Like most short peptides, thymosin alpha-1 is susceptible to hydrolysis under strongly acidic or basic conditions and to oxidation when exposed to air over long periods. The acetylated amino terminus blocks one common degradation route, which contributes to the molecule's relative robustness in solution. Lyophilized material generally retains potency for extended periods when kept cold and dry. Once reconstituted, aqueous solutions are less stable and are typically used within a defined window rather than held indefinitely at ambient temperature.
Routine handling calls for storage of the lyophilized powder at refrigerated temperatures, away from light, in a sealed container. Working solutions are often prepared in sterile water or buffer and kept cold between uses. Repeated freeze-thaw cycles are generally avoided because they can promote aggregation and loss of material. Laboratories usually record lot number, reconstitution date, and storage conditions so that any change in behavior can be traced to a specific preparation.
Promising results of therapeutic candidates are reported: phase I trialed ultrasound BBB-opening device against brain cancer (1 May), phase I trialed personalized mRNA vaccine against pancreatic cancer recurrence (10 May), a novel antibiotic (Streptothricin F) against ABR bacteria (9 May), an e-skin for prosthetic sensing (18 May), two-dose JYNNEOS vaccine against mpox appears ~86% (19 May) or ~66% (18 May) effective, and a xenografted mice-tested pan-KRAS-inhibitor against cancer (31 May).
The same protein ingredients marketed as dietary supplements can be incorporated into meal replacement and medical food products, but those are regulated and labeled differently from supplements. In the United States, "meal replacement" products are foods and are labeled as such. These typically contain protein, carbohydrates, fats, vitamins and minerals. There may be content claims such as "good source of protein", "low fat" or "lactose free". Medical foods, also nutritionally complete, are designed to be used while a person is under the care of a physician or other licensed healthcare professional. Liquid medical food products – for example, Ensure – are available in regular and high protein versions. Proteins are chains of amino acids. Nine of these proteinogenic amino acids are considered essential for humans because they cannot be produced from other compounds by the human body and so must be taken in as food. Recommended intakes, expressed as milligrams per kilogram of body weight per day, have been established. Other amino acids may be conditionally essential for certain ages or medical conditions. Amino acids, individually and in combinations, are sold as dietary supplements. The claim for supplementing with the branched-chain amino acids leucine, valine and isoleucine is for stimulating muscle protein synthesis. A review of the literature concluded this claim was unwarranted. In elderly people, supplementation with just leucine resulted in a modest (0.99 kg) increase in lean body mass.
Designed for the Kill: The Jet Fighter—Development and Experience. United States Naval Institute, 1995, ISBN 0-87021-059-9. Stevenson, James. The Pentagon Paradox: The Development of the F-18 Hornet. Naval Institute Press, 1993, ISBN 1-55750-775-9. Tillman, Barrett. Hellcat Aces of World War 2. London: Osprey Aerospace, 1996. ISBN 1-85532-596-9. United States Air Force Museum Guidebook. Wright-Patterson AFB, Ohio: Air Force Museum Foundation, 1975. United States Army Air Force. AN 01-60JE-2: Maintenance and Erection Instructions for Army Model P-51D-5, −10, −15, 20, −25; P-51K-1, −5, −10, −15; British Model Mustang IV Aeroplanes. Evansville, Indiana: U.S.A.A.F, 1944. Wagner, Ray. American Combat Planes of the 20th Century. Reno, Nevada: Jack Bacon & Company, 2004. ISBN 978-0-930083-17-5. Wagner, Ray. Mustang Designer: Edgar Schmued and the P-51. Herndon, Virginia: Smithsonian Institution Press, 2000. ISBN 978-1-56098-994-3. Walker, Jeff. "Empire of the Sun." Air Classics, Volume 24, Number 1, January 1988. White, Graham. Allied Aircraft Piston Engines of World War II. Warrendale, Pennsylvania: Society for Automotive Engineers, 1995. ISBN 1-56091-655-9. Wilson, Stewart, ed. "Mustang Warbirds: Civil Registered Mustangs of Australia and New Zealand Then and Now." Warbirds of Australia and New Zealand 2010. St Leonards, New South Wales, Australia: Chevron Publishing Group, 2010. Wixey, Ken. "Magnificent Mustang: A Production History of the North American P-51." Air Enthusiast, Issue 95, September/October 2001. Yenne, Bill: Rockwell: The Heritage of North American.
The Protein Structure Initiative (PSI) was a USA based project that aimed at accelerating discovery in structural genomics and contribute to understanding biological function. Funded by the U.S. National Institute of General Medical Sciences (NIGMS) between 2000 and 2015, its aim was to reduce the cost and time required to determine three-dimensional protein structures and to develop techniques for solving challenging problems in structural biology, including membrane proteins. Over a dozen research centers have been supported by the PSI for work in building and maintaining high-throughput structural genomics pipelines, developing computational protein structure prediction methods, organizing and disseminating information generated by the PSI, and applying high-throughput structure determination to study a broad range of important biological and biomedical problems. The project has been organized into three separate phases. The first phase of the Protein Structure Initiative (PSI-1) spanned from 2000 to 2005, and was dedicated to demonstrating the feasibility of high-throughput structure determination, solving unique protein structures, and preparing for a subsequent production phase. The second phase, PSI-2, focused on implementing the high-throughput structure determination methods developed in PSI-1, as well as homology modeling and addressing bottlenecks like modeling membrane proteins.
Rapamycin (Sirolimus) inhibits mTORC1, resulting in the suppression of cellular senescence. This appears to provide most of the beneficial effects of the drug (including life-span extension in animal studies). Suppression of insulin resistance by sirtuins accounts for at least some of this effect. Impaired sirtuin 3 leads to mitochondrial dysfunction. Rapamycin has a more complex effect on mTORC2, inhibiting it only in certain cell types under prolonged exposure. Disruption of mTORC2 produces the diabetic-like symptoms of decreased glucose tolerance and insensitivity to insulin.
Sources: en.wikipedia.org
In contrast, the accidental forms of S are its non-essential properties—properties that S can lose or gain without changing into a different kind of substance: the chick can lose its feathers (due to, e.g., parasites or the like) without ceasing to be an individual chicken.
=== Food sources === Hydra, as a carnivorous cnidarian, mainly feeds on small aquatic invertebrates. Hydra can also eat worms, young insects, larval mollusks, bluegill larvae, tiny crustaceans (e.g., Daphnia, Cyclops, ostracods, cladocerans, and copepods), and algaes (e.g., Cocconeis placentula, Cyclotella meneghineana, and Navicula zanoni). Some species of Hydra exist in a mutual relationship with various types of unicellular algae. The algae are protected from predators by Hydra; in return, photosynthetic products from the algae are beneficial as a food source to Hydra and even help to maintain the Hydra microbiome. There is an entire clade of "green hydra" where the species can stably maintain a population of Chlorella internally, with the main representative being Hydra viridissima. There are at least 4 species in this clade. The other species are called "brown hydra". There exists an immature symbiotic relationship between some strains of Hydra vulgaris and Chlorococcum.
== Mechanism of action == In-vitro binding inhibition data showed that Epelsiban is a highly potent and selective non-peptide oxytocin antagonist with sub-namomolar potency at the human oxytocin receptor (hOTR) Ki = 0.13 nM and with>50000-fold, >63000-fold, and >31000-fold selectivity over the human V1a, V1b and V2 vasopressin receptors. It is also 100-fold more potent at the hOTR than atosiban (a marketed intravenous peptide oxytocin antagonist) and is 5-fold more potent against the hOTR, and more selective against the human vasopressin receptors, especially V2, than retosiban. High in vivo oxytocin antagonist potency was demonstrated in the anesthetized rat model, where uterine contractions were elicited by intravenous administration of oxytocin and reduction in uterine contractility was measured after subsequent intravenous administrations of increasing doses of Epelsiban, which gave an IC50 of 192nM.
=== Diagnosis === Diagnosis of uterine prolapse is based on a history of symptoms, which may include symptom questionnaires, and a physical exam. Usually, the physical exam involves a vaginal exam, often with a speculum, and a pelvic exam. The extent and severity of prolapse is commonly documented using the Pelvic Organ Prolapse Quantification (POP-Q) system.
== Production of biopharmaceuticals == Lemna has been transformed by molecular biologists to express proteins of pharmaceutical interest. Expression constructs were engineered to cause Lemna to secrete the transformed proteins into the growth medium at high yield. Since the Lemna is grown on a simple medium, this substantially reduces the burden of protein purification in preparing such proteins for medical use, promising substantial reductions in manufacturing costs. In addition, the host Lemna can be engineered to cause secretion of proteins with human patterns of glycosylation, an improvement over conventional plant gene-expression systems. Several such products are being developed, including monoclonal antibodies.
Sources: en.wikipedia.org
== Chemical modifications == Creating chemically stable short oligonucleotides was the earliest challenge in developing ASO therapies. Naturally occurring oligonucleotides are easily degraded by nucleases, an enzyme that cleaves nucleotides and is ample in every cell type. Short oligonucleotide sequences also have weak intrinsic binding affinities, which contributes to their degradation in vivo.
Because PAI-2 is not properly secreted it accumulates in the cell where it remains unglycosylated. The exposed RCL loop on the PAI-2 contains the sequence Arg380-Thr381 which is identical to the cleavage site uPA/tPA identity. When uPA/tPA bind and cleave the bond between Arg-380 and Thr381 the RCL loop inserts itself into a β-sheet A slot in the enzyme(s) and conformationally alters the active site of the enzyme allowing it to no longer function.
The incompressible Navier–Stokes equations with uniform density and viscosity and conservative external field is the fundamental equation of hydraulics. The domain for these equations is commonly a 3 or fewer dimensional Euclidean space, for which an orthogonal coordinate reference frame is usually set to explicit the system of scalar partial differential equations to be solved. In 3-dimensional orthogonal coordinate systems are 3: Cartesian, cylindrical, and spherical. Expressing the Navier–Stokes vector equation in Cartesian coordinates is quite straightforward and not much influenced by the number of dimensions of the euclidean space employed, and this is the case also for the first-order terms (like the variation and convection ones) also in non-cartesian orthogonal coordinate systems. But for the higher order terms (the two coming from the divergence of the deviatoric stress that distinguish Navier–Stokes equations from Euler equations) some tensor calculus is required for deducing an expression in non-cartesian orthogonal coordinate systems. A special case of the fundamental equation of hydraulics is the Bernoulli's equation. The incompressible Navier–Stokes equation is composite, the sum of two orthogonal equations,
=== Related books === In 1991, Pryor published his first book about Flag Fen, entitled Flag Fen: Prehistoric Fenland Centre, as one of a series co-produced by English Heritage and B.T. Batsford. The final monograph on the site – entitled The Flag Fen Basin: Archaeology and environment of a Fenland Landscape – was published in 2001 as an English Heritage Archaeological Report. The report is now available online through the Archaeology Data Service. Pryor has followed this with a third book on the site, published by Tempus in 2005. Entitled Flag Fen: Life and Death of a Prehistoric Landscape, it is what he has described as a "major revision" of his 1991 work, for instance repudiating his earlier "lake village" concept.
Sources: en.wikipedia.org
它促进未成熟T细胞分化并增强成熟T细胞的增殖与细胞因子分泌。这些作用有助于放大抗原特异性免疫应答。
目前认为它可能通过Toll样受体等模式识别受体传递信号，但精确的受体身份和结合机制尚未完全阐明。
不同试验在患者选择、给药方案、联合治疗和终点定义上差异很大。这些异质性使得跨研究比较困难，结论难以统一。
It is usually classified as an immunomodulatory peptide rather than a classical hormone. It derives from the larger protein prothymosin alpha and acts mainly on immune cells. The thymosin label covers a group of distinct peptides, so the naming can be misleading.